Cognitive · Research Phase
Bromantane-adjacent Peptides
No lawful US pathway
01 · Overview
Bromantane-adjacent peptides refer to a theoretical class of compounds that might share functional goals with bromantane, a synthetic adamantane derivative developed in Russia and classed as an actoprotector, or synthetic adaptogen intended to improve mental and physical performance (PMID 24009833). In rats, bromantane altered brain dopamine and serotonin parameters, consistent with mild psychostimulant activity (PMID 7580761).
Bromantane itself is not a peptide, and peptide analogs designed to mimic its dopaminergic or anti-asthenic effects are a speculative concept rather than an established research program.
02 · Research summary & key findings
No validated peptide candidates in this category have been described in the peer-reviewed literature. The concept rests on the pharmacology of bromantane, which in a large uncontrolled Russian multicenter study of 728 patients with asthenic disorders was reported to reduce asthenia with few adverse effects (PMID 21322821); this evidence concerns bromantane, not any peptide. This remains a speculative area with no preclinical or clinical evidence for peptide versions to date.
03 · Regulatory status
Bromantane-adjacent Peptides is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Bromantane-adjacent Peptides is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
Bromantane-adjacent Peptides is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Not established
References
- [1][Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten] Zh Nevrol Psikhiatr Im S S Korsakova, 2010. PMID 21322821
- [2]The pharmacology of actoprotectors: practical application for improvement of mental and physical performance Biomol Ther (Seoul), 2012. PMID 24009833
- [3][The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain] Eksp Klin Farmakol, 1995. PMID 7580761
Primary literature
- PubMed: "Bromantane-adjacent Peptides"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Bromantane-adjacent Peptides"
Registered interventional and observational studies, including status and phase.
- PubChem: "Bromantane-adjacent Peptides"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.